Summary:
In adults with preexisting cardiovascular disease, overweight or obesity, and no prior diagnosis of diabetes, semaglutide (GLP-1 receptor agonist) administered for up to 208 weeks significantly reduced body weight (-10.2%) compared to placebo (-1.5%), with anthropometric improvements in waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%), and fewer serious adverse events but higher discontinuation rates, particularly in lower BMI categories.
| PICO | Description |
|---|---|
| Population | Adults with preexisting cardiovascular disease, overweight or obesity, and no prior diagnosis of diabetes. |
| Intervention | Administration of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for an extended period of up to 208 weeks to evaluate weight loss and safety outcomes. |
| Comparison | Placebo group evaluated for weight loss and safety outcomes over the same duration of up to 208 weeks. |
| Outcome | Semaglutide treatment consistently resulted in a clinically significant weight loss (-10.2%) compared to placebo (-1.5%). Anthropometric improvements, such as reductions in waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%), were observed. Fewer serious adverse events occurred in semaglutide groups across various BMI categories, though higher rates of trial product discontinuation were noted, especially in lower BMI categories. |
Source: Ryan, Donna H., et al. “Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.” Nature Medicine, 2024 Jul. Read article here.
